Tag: FDA warning letters

Handling Data Integrity Issues in Cross-Site Stability Testing

As pharmaceutical operations scale globally, it’s increasingly common to distribute stability testing across multiple sites. However, this decentralized approach introduces challenges in maintaining data integrity, especially when sites use different systems, practices, or oversight structures. This article explores practical strategies to mitigate data integrity issues during cross-site stability testing, while ensuring full GxP compliance and…

Best Practices for Stability Testing Data Integrity, Pharmaceutical Quality and Practices

FDA Guidance on Data Integrity for Stability Testing

Data integrity continues to be a top concern in FDA inspections across pharmaceutical facilities. Especially in stability testing, where long-term data supports product shelf life and regulatory claims, ensuring reliable and traceable data is crucial. This article explores the FDA’s guidance on data integrity and how pharma professionals can align their stability testing operations to…

Best Practices for Stability Testing Data Integrity, Pharmaceutical Quality and Practices

GMP Requirements for Stability Data Integrity

In the highly regulated world of pharmaceuticals, stability studies play a pivotal role in determining the shelf life and storage conditions of drug products. However, the reliability of these studies hinges entirely on the integrity of the data generated. Regulatory agencies such as the USFDA, EMA, and CDSCO have consistently emphasized data integrity as a…

Good Manufacturing Practices (GMP) for Stability Studies, Pharmaceutical Quality and Practices